Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21254.
   PubMed Web of Science ®Google Scholar
• Han F, He J, Li F, et al. Emerging roles of microRNAs in EGFR-targeted therapies for lung cancer. Biomed Res Int. 2015;2015:672759. doi:10.1155/2015/672759.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J. 2014;20:281–289. doi:10.1097/PPO.0000000000000063.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550. doi:10.1056/NEJMoa061884.
   PubMed Web of Science ®Google Scholar
• Chuang JC, Neal JW, Niu XM, et al. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: current data and future prospects. Lung Cancer. 2015;90:1–7. doi:10.1016/j.lungcan.2015.07.016.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Campo MJ, Dahlberg SE, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015;10:S1–63. doi:10.1097/JTO.0000000000000405.
   PubMed Web of Science ®Google Scholar
• Delaney C, Frank S, Huang RS. Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. Chin J Cancer. 2015;34:149–160. doi:10.1186/s40880-015-0007-9.
   PubMed Web of Science ®Google Scholar
• Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2:e1129. doi:10.1371/journal.pone.0001129.
   PubMed Web of Science ®Google Scholar
• Bartosch C, Afonso M, Pires-Luis AS, et al. Distant metastases in uterine leiomyosarcomas: the wide variety of body sites and time intervals to metastatic relapse. Int J Gynecol Pathol. 2016. doi:10.1097/PGP.0000000000000284.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy. 2016;8:279–298. doi:10.2217/imt.15.123.
   PubMed Web of Science ®Google Scholar
• Sgambato A, Casaluce F, Sacco PC, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management. Curr Drug Saf. 2016;11:62–68.
   PubMed Web of Science ®Google Scholar
• Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. 2016;21:643–650. doi:10.1634/theoncologist.2015-0498.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Benna C, Pilati P. Coinhibitory molecules in cancer biology and therapy. Cytokine Growth Factor Rev. 2013;24:147–161. doi:10.1016/j.cytogfr.2013.01.003.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J Clin Pharmacol. 2016;56:157–169. doi:10.1002/jcph.591.
   PubMed Web of Science ®Google Scholar
• Su H, Zhao X, Huang X, et al. Molecular cloning and characterization of the full-length cDNA encoding the porcine CD28. Vet Immunol Immunopathol. 2012;146:264–269. doi:10.1016/j.vetimm.2012.03.014.
   PubMed Web of Science ®Google Scholar
• Latza U, Durkop H, Schnittger S, et al. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol. 1994;24:677–683. doi:10.1002/eji.1830240329.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Pastor F, Rodriguez A, et al. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol. 2015;42:640–655. doi:10.1053/j.seminoncol.2015.05.014.
   PubMed Web of Science ®Google Scholar
• Bartkowiak T, Curran MA. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front Oncol. 2015;5:117. doi:10.3389/fonc.2015.00117.
   PubMed Web of Science ®Google Scholar
• Cheung TC. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway. Recent Pat DNA Gene Seq. 2009;3:177–182.
   PubMedGoogle Scholar
• Foy SP, Mandl SJ, Dela Cruz T, et al. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Cancer Immunol Immunother. 2016. doi:10.1007/s00262-016-1816-7.
   PubMed Web of Science ®Google Scholar
• Nishino M, Chambers ES, Chong CR, et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res. 2016. doi:10.1158/2326-6066.CIR-15-0267.
   PubMed Web of Science ®Google Scholar
• Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536–541. doi:10.1038/415536a.
   PubMed Web of Science ®Google Scholar
• Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One. 2014;9:e109080. doi:10.1371/journal.pone.0109080.
   PubMed Web of Science ®Google Scholar
• Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res. 2015;21:976–984. doi:10.1158/1078-0432.CCR-14-1187.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014;20:256–261. doi:10.1097/PPO.0000000000000061.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. doi:10.1038/nm730.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389–395. doi:10.1038/cmi.2010.28.
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25. doi:10.1016/j.coi.2014.01.004.
   PubMed Web of Science ®Google Scholar
• Anna M, Silvia DS, Riccardo D, et al. Reverse immunoediting: when immunity is edited by antigen. Immunol Lett. 2016;175:16–20. doi:10.1016/j.imlet.2016.04.015.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989–2003. doi:10.1084/jem.20101158.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–1570. doi:10.1126/science.1203486.
   PubMed Web of Science ®Google Scholar
• Madureira P, de Mello RA, de Vasconcelos A, et al. Immunotherapy for lung cancer: for whom the bell tolls? Tumour Biol. 2015;36:1411–1422. doi:10.1007/s13277-015-3285-6.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567. doi:10.1038/nature14011.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Horn L, Gandhi L, et al. Nivolumab(anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. J Clin Oncol. 2014;32(suppl); abstr 8112. doi:10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol. 2014;32(suppl); abstr 8024. doi:10.1200/JCO.2013.54.6911.
   Web of Science ®Google Scholar
• Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(suppl); abstr 8007. doi:10.1200/JCO.2013.54.6911.
   Web of Science ®Google Scholar
• Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(Suppl);abstr 8020. doi:10.1200/JCO.2013.54.6911.
   Web of Science ®Google Scholar
• Brahmer JR, Rizvi NA, Lutzky J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol. 2014;32(suppl); abstr 8021. doi:10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. doi:10.1056/NEJMoa1501824.
   PubMed Web of Science ®Google Scholar
• Gunturi A, McDermott DF. Nivolumab for the treatment of cancer. Expert Opin Investig Drugs. 2015;24:253–260. doi:10.1517/13543784.2015.991819.
   PubMed Web of Science ®Google Scholar
• Scarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context. 2015;4:212289. doi:10.7573/dic.212289.
   PubMedGoogle Scholar
• Tomasini P, Khobta N, Greillier L, et al. Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol. 2012;4:43–50. doi:10.1177/1758834011431718.
   PubMed Web of Science ®Google Scholar
• Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol. 2010;37:450–454. doi:10.1053/j.seminoncol.2010.09.010.
   PubMed Web of Science ®Google Scholar
• Monteiro ID, Califano R, Mountzios G, et al. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. Future Oncol. 2016;12:551–564. doi:10.2217/fon.15.309.
   PubMed Web of Science ®Google Scholar
• Pilotto S, Molina-Vila MA, Karachaliou N, et al. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Transl Lung Cancer Res. 2015;4:721–727. doi:10.3978/j.issn.2218-6751.2015.10.11.
   PubMedGoogle Scholar
• Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265. doi:10.1016/S1470-2045(15)70054-9.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004–2012. doi:10.1200/JCO.2014.58.3708.
   PubMed Web of Science ®Google Scholar
• Spira AI, Park K, Mazières J, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol. 2015;33(Suppl. 15):8028.
   Google Scholar
• Zatloukal P, Heo DS, Park K, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27(suppl); abstr 8071.
   Google Scholar
• Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17–37. doi:10.1007/82_2010_116.
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011;1217:45–59. doi:10.1111/j.1749-6632.2010.05919.x.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634–642. doi:10.1634/theoncologist.2015-0507
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–3175. doi:10.1200/JCO.2009.26.7609.
   PubMed Web of Science ®Google Scholar
• Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park). 2014;28(Suppl 3):30–38.
   PubMed Web of Science ®Google Scholar
• Rounds A, Kolesar J. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. Am J Health Syst Pharm. 2015;72:1851–1855. doi:10.2146/ajhp150235.
   PubMed Web of Science ®Google Scholar
• Ang YL, Lim JS, Soo RA. Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. Onco Targets Ther. 2016;9:3187–3195. doi:10.2147/OTT.S84356.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther. 2014;7:567–573. doi:10.2147/OTT.S59959.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31(suppl); abstr 8008. doi:10.1200/JCO.2013.49.0219.
   Web of Science ®Google Scholar
• Brahmer JR, Rizvi NA, Lutzky J. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol. 2014;32(suppl); abstr 8023. doi:10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046–2054. doi:10.1200/JCO.2011.38.4032.
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24:75–83. doi:10.1093/annonc/mds213.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko IN, Luft A, et al. Phase II trial of ipilimumab and paclitaxel/carboplatin in first-line stage IIIb/IV non-small cell lung cancer. J Clin Oncol. 2010;28(suppl); abstr 7531. doi:10.1200/JCO.2009.21.9618.
   Web of Science ®Google Scholar
• Helissey C, Champiat S, Soria JC. Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015;27:108–117. doi:10.1097/CCO.0000000000000167.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71:161–169. doi:10.1016/j.jaad.2014.02.035.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–1022. doi:10.1038/ni.2703.
   PubMed Web of Science ®Google Scholar
• Kvistborg P, Philips D, Kelderman S, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6:254ra128. doi:10.1126/scitranslmed.3008918.
   PubMed Web of Science ®Google Scholar
• Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32–38. doi:10.1016/j.coph.2015.05.011.
   PubMed Web of Science ®Google Scholar
• Pan ZK, Ye F, Wu X, et al. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2015;7:462–470. doi:10.3978/j.issn.2072-1439.2015.02.13.
   PubMed Web of Science ®Google Scholar
• Champiat S, Ileana E, Giaccone G, et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol. 2014;9:144–153. doi:10.1097/JTO.0000000000000074.
   PubMed Web of Science ®Google Scholar
• Drake CG. Combined immune checkpoint blockade. Semin Oncol. 2015;42:656–662. doi:10.1053/j.seminoncol.2015.05.002.
   PubMed Web of Science ®Google Scholar
• Teng F, Kong L, Meng X, et al. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 2015;365:23–29. doi:10.1016/j.canlet.2015.05.012.
   PubMed Web of Science ®Google Scholar
• Horinouchi H, Yamamoto N, Fujiwara Y, et al. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs. 2015;33:881–889. doi:10.1007/s10637-015-0243-5.
   PubMed Web of Science ®Google Scholar
• Daly ME, Monjazeb AM, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer. J Thorac Oncol. 2015;10:1685–1693. doi:10.1097/JTO.0000000000000686.
   PubMed Web of Science ®Google Scholar
• Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299–308. doi:10.1016/S1470-2045(15)00544-6.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Brahmer JR, Gettinger S, et al. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(suppl); abstr 8113. doi:10.1200/JCO.2013.54.6911.
   Web of Science ®Google Scholar
• Gettinger S, Rizvi N, Chow LM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PTDC) or erlotinib (ERL) in advanced nonsmall cell lung cancer (NSCLC). Ann Oncol. 2014;25(Suppl 4);abstr 1054PD. doi:10.1093/annonc/mdu203.
   Web of Science ®Google Scholar
• Simone CB 2nd, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res. 2015;4:545–552. doi:10.3978/j.issn.2218-6751.2015.10.05.
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237–251. doi:10.1038/nrc3237.
   PubMed Web of Science ®Google Scholar
• D’Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112:95–102. doi:10.1038/bjc.2014.555.
   PubMed Web of Science ®Google Scholar
• Angell TE, Lechner MG, Jang JK, et al. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014;20:6034–6044. doi:10.1158/1078-0432.CCR-14-0879.
   PubMed Web of Science ®Google Scholar
• Carter CA, Rajan A, Keen C, et al. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016;27:693–699. doi:10.1093/annonc/mdw008.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31:4311–4318. doi:10.1200/JCO.2013.51.4802.
   PubMed Web of Science ®Google Scholar
• Jia M, Feng W, Kang S, et al. Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J Thorac Dis. 2015;7:455–461. doi:10.3978/j.issn.2072-1439.2015.02.06.
   PubMed Web of Science ®Google Scholar
• Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371–381. doi:10.1530/ERC-13-0499.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Goldberg SB, Balmanoukian AS, et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol. 2015;3(suppl);abstr 3014.
   Google Scholar
• Creelan BC, Chow LQ, Kim D, et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl); abstr 3047.
   Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Aguiar PN Jr., Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016;8:479–488. doi:10.2217/imt-2015-0002.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–5074. doi:10.1158/1078-0432.CCR-13-3271.
   PubMed Web of Science ®Google Scholar
• Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer. J Thorac Oncol. 2015;10:1726–1735. doi:10.1097/JTO.0000000000000687.
   PubMed Web of Science ®Google Scholar
• Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22:807–812. doi:10.1158/1078-0432.CCR-14-3175.
   PubMed Web of Science ®Google Scholar
• Ma W, Gilligan BM, Yuan J, et al. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9:47. doi:10.1186/s13045-016-0277-y.
   PubMed Web of Science ®Google Scholar
• Zhong A, Xing Y, Pan X, et al. Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis. Onco Targets Ther. 2015;8:3595–3601. doi:10.2147/OTT.S91469.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–1544. doi:10.1182/blood-2008-12-195792.
   PubMed Web of Science ®Google Scholar
• Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol. 2016; doi:10.1001/jamaoncol.2016.0639. [Epub ahead of print].
   Google Scholar